WebSite > TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

  • Company Name TargetMol Chemicals Inc.
  • Tel -+1-781-999-5354;
  • Email marketing@targetmol.com
  • WebSite https://www.targetmol.com/
  • CB Index 58
  •       Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
TargetMol Chemicals Inc. Product List
  •  
  •  
  •  
  •  
  •  
  • Product Name Jadomycin B
  • MF C30H31NO9
  • CAS 149633-99-8
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name Altromycin G
  • MF C45H55NO18
  • CAS 134887-79-9
  •  
  •  
  • Product Name Bikaverin
  • MF C20H14O8
  • CAS 33390-21-5
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name Mycothiol
  • MF C17H30N2O12S
  • CAS 192126-76-4
  •  
  •  
  • Product Name SM-6586
  • MF C26H27N5O5
  • CAS 103898-38-0
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name Masilukast
  • MF C31H32F3N3O5S
  • CAS 136564-68-6
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name Idremcinal
  • MF C39H69NO12
  • CAS 110480-13-2
  •  
  •  
  •  
  •  
  •  
  • Product Name Hypeptin
  • MF C44H71N13O15
  • CAS 124883-38-1
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •